|
|
||||||||
14i NKT Cells1




* Ludwig Institute for Cancer Research, Epalinges, Switzerland; and
Experimental Immunology Unit, Cancer Immunotherapy and Gene Therapy Program, Department of Oncology, Dipartimento di Biotecnologie, H. San Raffaele Scientific Institute, Milan, Italy
CD1d-dependent invariant V
14 (V
14i) NKT cells are innate T lymphocytes expressing a conserved semi-invariant TCR, consisting, in mice, of the invariant V
14-J
18 TCR
-chain paired mostly with V
8.2 and V
7. The cellular requirements for thymic positive and negative selection of V
14i NKT cells are only partially understood. Therefore, we generated transgenic mice expressing human CD1d (hCD1d) either on thymocytes, mainly CD4+ CD8+ double positive, or on APCs, the cells implicated in the selection of V
14i NKT cells. In the absence of the endogenous mouse CD1d (mCD1d), the expression of hCD1d on thymocytes, but not on APCs, was sufficient to select V
14i NKT cells that proved functional when activated ex vivo with the Ag
-galactosyl ceramide. V
14i NKT cells selected by hCD1d on thymocytes, however, attained lower numbers than in control mice and expressed essentially V
8.2. The low number of V
8.2+ V
14i NKT cells selected by hCD1d on thymocytes was not reversed by the concomitant expression of mCD1d, which, instead, restored the development of V
7+ V
14i NKT cells. V
8.2+, but not V
7+, NKT cell development was impaired in mice expressing both hCD1d on APCs and mCD1d. Taken together, our data reveal that selective CD1d expression by thymocytes is sufficient for positive selection of functional V
14i NKT cells and that both thymocytes and APCs may independently mediate negative selection.
This article has been cited by other articles:
![]() |
S. Huang, E. Martin, S. Kim, L. Yu, C. Soudais, D. H. Fremont, O. Lantz, and T. H. Hansen MR1 antigen presentation to mucosal-associated invariant T cells was highly conserved in evolution PNAS, May 19, 2009; 106(20): 8290 - 8295. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. I. Zimmer, H. P. Nguyen, B. Wang, H. Xu, A. Colmone, K. Felio, H.-J. Choi, P. Zhou, M.-L. Alegre, and C.-R. Wang Polymorphisms in CD1d affect antigen presentation and the activation of CD1d-restricted T cells PNAS, February 10, 2009; 106(6): 1909 - 1914. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Tonti, G. Galli, C. Malzone, S. Abrignani, G. Casorati, and P. Dellabona NKT-cell help to B lymphocytes can occur independently of cognate interaction Blood, January 8, 2009; 113(2): 370 - 376. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ueno, J. Wang, L. Cheng, J. S. Im, Y. Shi, S. A. Porcelli, and Y. Yang Enhanced Early Expansion and Maturation of Semi-Invariant NK T Cells Inhibited Autoimmune Pathogenesis in Congenic Nonobese Diabetic Mice J. Immunol., November 15, 2008; 181(10): 6789 - 6796. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Williams, J. M. Lumsden, X. Yu, L. Feigenbaum, J. Zhang, S. M. Steinberg, and R. J. Hodes Regulation of Thymic NKT Cell Development by the B7-CD28 Costimulatory Pathway J. Immunol., July 15, 2008; 181(2): 907 - 917. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yu and M. T. Cantorna The vitamin D receptor is required for iNKT cell development PNAS, April 1, 2008; 105(13): 5207 - 5212. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kishimoto, T. Ohteki, N. Yajima, K. Kawahara, M. Natsui, S. Kawarasaki, K. Hamada, Y. Horie, Y. Kubo, S. Arase, et al. The Pten/PI3K pathway governs the homeostasis of V{alpha}14iNKT cells Blood, April 15, 2007; 109(8): 3316 - 3324. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Dougan, P. Rava, M. M. Hussain, and R. S. Blumberg MTP regulated by an alternate promoter is essential for NKT cell development J. Exp. Med., March 19, 2007; 204(3): 533 - 545. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Schumann, M. P. Mycko, P. Dellabona, G. Casorati, and H. R. MacDonald Cutting Edge: Influence of the TCR Vbeta Domain on the Selection of Semi-Invariant NKT Cells by Endogenous Ligands J. Immunol., February 15, 2006; 176(4): 2064 - 2068. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |